The Promise of Bacteriophage Therapy Rekindled but Hurdles Remain

Antibiotic resistance is a mounting public health concern with the  CDC estimating the annual added cost of treating antibiotic-resistant infections at $20 billion in the US alone. The CDC also estimates that 50-70% of hospital-acquired infections are now resistant to first-line antibiotics. Given the dearth of new classes of antibiotics, drug companies are looking at non-traditional approaches … Read more

GMP Issues for 3D Printed Pills Resolved But Is It Really a Big Deal?

On 31st July 2015, FDA approved the World’s first 3D printed pill and it was widely celebrated as a major milestone and, in my ways it is, but for the reasons one may think. The approval is for a new formulation of a well-established epilepsy drug, levetiracetam, called Spritam®. With more than 80 generic drugs containing levetiracetam in … Read more